---
title: "Precigen, Inc. (PGEN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PGEN.US.md"
symbol: "PGEN.US"
name: "Precigen, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T15:55:36.981Z"
locales:
  - [en](https://longbridge.com/en/quote/PGEN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PGEN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PGEN.US.md)
---

# Precigen, Inc. (PGEN.US)

## Company Overview

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [recigen.com](https://recigen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 103 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 652.08% |  |
| Net Profit YoY | -144.76% |  |
| P/B Ratio | 73.29 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1483085676.80 |  |
| Revenue | 31595000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12418.40% | E |
| Profit Margin | -646.99% | E |
| Gross Margin | 64.75% | A |
| Revenue YoY | 652.08% | A |
| Net Profit YoY | -144.76% | E |
| Total Assets YoY | 7.64% | B |
| Net Assets YoY | 30.90% | A |
| Cash Flow Margin | 30.08% | D |
| OCF YoY | 652.08% | A |
| Turnover | 0.24 | D |
| Gearing Ratio | 85.40% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Precigen, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "652.08%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-144.76%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "73.29",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1483085676.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "31595000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12418.40%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-646.99%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "64.75%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "652.08%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-144.76%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.64%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "30.90%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "30.08%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "652.08%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.24",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "85.40%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.87 | 344/386 | - | - | - |
| PB | 73.29 | 440/386 | 67.02 | 37.61 | 31.18 |
| PS (TTM) | 46.94 | 230/386 | 262.27 | 205.82 | 122.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Overweight | 1 | 33% |
| Hold | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.32 |
| Highest Target | 10.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PGEN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PGEN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PGEN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PGEN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**